Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study

Cheryl H. Waters, Kapil D. Sethi, Robert A. Hauser, Eric Molho, John M. Bertoni

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Zydis selegiline dissolves on contact with saliva and undergoes pregastric absorption. This minimizes first-pass metabolism and provides high plasma concentrations of selegiline. In this study, the efficacy and safety of Zydis selegiline was assessed in Parkinson's disease (PD) patients who were experiencing motor fluctuations with levodopa. Patients were randomly assigned to either drug or placebo in a 2:1 ratio in this double-blind, multicenter trial. Significant reductions in daily off time occurred at 4 to 6 weeks with the 1.25 mg dose (9.9%, P = 0.003) and 10 to 12 weeks with the 2.5 mg dose (13.2%, P < 0.001). The total number of off hours was reduced by 2.2 hours at Week 12 from baseline (compared with 0.6 hours in the placebo group). The average number of dyskinesia-free on hours for the Zydis selegiline patients increased by 1.8 hours at Week 12. There was no change in mean percentage of "Asleep" time throughout the study. No apparent differences were detected in the occurrence of drug-related adverse events between the Zydis selegiline group and placebo-treated groups. Adverse events were consistent with known effects of levodopa therapy. Zydis selegiline safely reduces daily off time when used as adjunctive therapy with levodopa in patients with PD.

Original languageEnglish (US)
Pages (from-to)426-432
Number of pages7
JournalMovement Disorders
Volume19
Issue number4
DOIs
StatePublished - Apr 1 2004

Fingerprint

Selegiline
Parkinson Disease
Placebos
Levodopa
Dyskinesias
Drug-Related Side Effects and Adverse Reactions
Saliva
Multicenter Studies
Safety
Therapeutics
Pharmaceutical Preparations

Keywords

  • Efficacy
  • MAO-B inhibition
  • Motor fluctuations
  • Parkinson's disease
  • Safety
  • Zydis selegiline

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations : A 3-month, randomized, placebo-controlled study. / Waters, Cheryl H.; Sethi, Kapil D.; Hauser, Robert A.; Molho, Eric; Bertoni, John M.

In: Movement Disorders, Vol. 19, No. 4, 01.04.2004, p. 426-432.

Research output: Contribution to journalArticle

@article{9195e5ee5faf4ec0983402d670bc639b,
title = "Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study",
abstract = "Zydis selegiline dissolves on contact with saliva and undergoes pregastric absorption. This minimizes first-pass metabolism and provides high plasma concentrations of selegiline. In this study, the efficacy and safety of Zydis selegiline was assessed in Parkinson's disease (PD) patients who were experiencing motor fluctuations with levodopa. Patients were randomly assigned to either drug or placebo in a 2:1 ratio in this double-blind, multicenter trial. Significant reductions in daily off time occurred at 4 to 6 weeks with the 1.25 mg dose (9.9{\%}, P = 0.003) and 10 to 12 weeks with the 2.5 mg dose (13.2{\%}, P < 0.001). The total number of off hours was reduced by 2.2 hours at Week 12 from baseline (compared with 0.6 hours in the placebo group). The average number of dyskinesia-free on hours for the Zydis selegiline patients increased by 1.8 hours at Week 12. There was no change in mean percentage of {"}Asleep{"} time throughout the study. No apparent differences were detected in the occurrence of drug-related adverse events between the Zydis selegiline group and placebo-treated groups. Adverse events were consistent with known effects of levodopa therapy. Zydis selegiline safely reduces daily off time when used as adjunctive therapy with levodopa in patients with PD.",
keywords = "Efficacy, MAO-B inhibition, Motor fluctuations, Parkinson's disease, Safety, Zydis selegiline",
author = "Waters, {Cheryl H.} and Sethi, {Kapil D.} and Hauser, {Robert A.} and Eric Molho and Bertoni, {John M.}",
year = "2004",
month = "4",
day = "1",
doi = "10.1002/mds.20036",
language = "English (US)",
volume = "19",
pages = "426--432",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations

T2 - A 3-month, randomized, placebo-controlled study

AU - Waters, Cheryl H.

AU - Sethi, Kapil D.

AU - Hauser, Robert A.

AU - Molho, Eric

AU - Bertoni, John M.

PY - 2004/4/1

Y1 - 2004/4/1

N2 - Zydis selegiline dissolves on contact with saliva and undergoes pregastric absorption. This minimizes first-pass metabolism and provides high plasma concentrations of selegiline. In this study, the efficacy and safety of Zydis selegiline was assessed in Parkinson's disease (PD) patients who were experiencing motor fluctuations with levodopa. Patients were randomly assigned to either drug or placebo in a 2:1 ratio in this double-blind, multicenter trial. Significant reductions in daily off time occurred at 4 to 6 weeks with the 1.25 mg dose (9.9%, P = 0.003) and 10 to 12 weeks with the 2.5 mg dose (13.2%, P < 0.001). The total number of off hours was reduced by 2.2 hours at Week 12 from baseline (compared with 0.6 hours in the placebo group). The average number of dyskinesia-free on hours for the Zydis selegiline patients increased by 1.8 hours at Week 12. There was no change in mean percentage of "Asleep" time throughout the study. No apparent differences were detected in the occurrence of drug-related adverse events between the Zydis selegiline group and placebo-treated groups. Adverse events were consistent with known effects of levodopa therapy. Zydis selegiline safely reduces daily off time when used as adjunctive therapy with levodopa in patients with PD.

AB - Zydis selegiline dissolves on contact with saliva and undergoes pregastric absorption. This minimizes first-pass metabolism and provides high plasma concentrations of selegiline. In this study, the efficacy and safety of Zydis selegiline was assessed in Parkinson's disease (PD) patients who were experiencing motor fluctuations with levodopa. Patients were randomly assigned to either drug or placebo in a 2:1 ratio in this double-blind, multicenter trial. Significant reductions in daily off time occurred at 4 to 6 weeks with the 1.25 mg dose (9.9%, P = 0.003) and 10 to 12 weeks with the 2.5 mg dose (13.2%, P < 0.001). The total number of off hours was reduced by 2.2 hours at Week 12 from baseline (compared with 0.6 hours in the placebo group). The average number of dyskinesia-free on hours for the Zydis selegiline patients increased by 1.8 hours at Week 12. There was no change in mean percentage of "Asleep" time throughout the study. No apparent differences were detected in the occurrence of drug-related adverse events between the Zydis selegiline group and placebo-treated groups. Adverse events were consistent with known effects of levodopa therapy. Zydis selegiline safely reduces daily off time when used as adjunctive therapy with levodopa in patients with PD.

KW - Efficacy

KW - MAO-B inhibition

KW - Motor fluctuations

KW - Parkinson's disease

KW - Safety

KW - Zydis selegiline

UR - http://www.scopus.com/inward/record.url?scp=2342426425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342426425&partnerID=8YFLogxK

U2 - 10.1002/mds.20036

DO - 10.1002/mds.20036

M3 - Article

C2 - 15077240

AN - SCOPUS:2342426425

VL - 19

SP - 426

EP - 432

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 4

ER -